PennyMac Financial Services, Inc. Announces Date for Release of First Quarter 2025 Results
The release, webcast, and accompanying materials will be available online at pfsi.pennymac.com. A replay of the webcast will be available shortly after its conclusion.
Individuals who are unable to access the website but would like to receive a copy of the materials should contact our Investor Relations department at 818.264.4907.
About PennyMac Financial Services, Inc.
PennyMac Financial Services, Inc. is a specialty financial services firm focused on the production and servicing of U.S. mortgage loans and the management of investments related to the U.S. mortgage market. Founded in 2008, the company is recognized as a leader in the U.S. residential mortgage industry and employs approximately 4,100 people across the country. For the twelve months ended December 31, 2024, PennyMac Financial's production of newly originated loans totaled $116 billion in unpaid principal balance, making it a top lender in the nation. As of December 31, 2024, PennyMac Financial serviced loans totaling $666 billion in unpaid principal balance, making it a top mortgage servicer in the nation. Additional information about PennyMac Financial Services, Inc. is available at pfsi.pennymac.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415258497/en/
Contacts
MediaKristyn Clarkmediarelations@pennymac.com 805.395.9943
Investors Kevin ChamberlainIsaac GardenPFSI_IR@pennymac.com 818.264.4907
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Scotiabank Upgrades Thermo Fisher (TMO) to Outperform, Lowers PT
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 11, Scotiabank upgraded its rating for Thermo Fisher Scientific Inc. (NYSE:TMO) from 'Sector Perform' to 'Outperform' while also setting a new price target of $590, down from the previous $605. The bank believes that the stock has been 'disproportionately impacted' because of healthcare and trade policy talks and changes this year. A workstation in a research lab stocked with laboratory products and services. Scotiabank expects Thermo Fisher Scientific Inc. (NYSE:TMO) to grow faster once the concerns about US healthcare policy changes go away. This growth is expected to be driven by the company's 'unparalleled commercial scale' and improved region-for-region capabilities anticipated by 2026. The firm also pointed out that Thermo Fisher Scientific Inc.'s (NYSE:TMO) leading position in innovation, operational execution, and cash flow potential as key strengths that position the company well in the life science tools industry. In this industry, Thermo Fisher Scientific Inc. (NYSE:TMO) is the largest company 'by a significant margin.' Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading life science and clinical research company that supplies analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical, and biotechnology services. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Raymond James Raises Charles Schwab PT, Keeps Outperform Rating
The Charles Schwab Corporation (NYSE:SCHW) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 8, Raymond James increased its price target for The Charles Schwab Corporation (NYSE:SCHW) from $91 to $99 while keeping an 'Outperform' rating. The research firm expects The Charles Schwab Corporation (NYSE:SCHW) to mostly pay down its high-cost funding by the end of 2025, which should help improve the company's net interest margin. A corporate finance professional studying a financial performance chart. Raymond James also pointed out that the market volatility is currently elevated, which is driving strong trading volumes. This should help offset any net interest margin headwinds from possible Federal Reserve rate cuts in 2025. Raymond James analysts also highlighted improving trends in net new assets and account growth at The Charles Schwab Corporation (NYSE:SCHW). Looking ahead, the firm sees strong potential for earnings per share growth for The Charles Schwab Corporation (NYSE:SCHW) in 2025 and 2026, with the possibility of gains in the stock's valuation. The Charles Schwab Corporation (NYSE:SCHW) is an American multinational financial services company that provides a full range of brokerage, banking, and financial advisory services through its operating subsidiaries. While we acknowledge the potential of SCHW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Pfizer (PFE) Reports XTANDI Shows Life-Extending Benefits
Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study. This study looked at how XTANDI (enzalutamide), in combination with leuprolide and as a monotherapy, works for men who have a type of prostate cancer called non-metastatic hormone-sensitive prostate cancer (nmHSPC), which is also known as nonmetastatic castration-sensitive prostate cancer or (nmCSPC). The men who were a part of the study had a return of signs of cancer, called biochemical recurrence (BCR), and were at high risk for metastasis. A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. For patients who took XTANDI plus leuprolide, the study showed a clear and important improvement in overall survival compared to those who were treated with placebo plus leuprolide. The study showed that using XTANDI can help extend life for men with nmHSPC and high-risk BCR. Currently, XTANDI is approved in over 80 countries, including the US, the European Union, and Japan. Pfizer Inc. (NYSE:PFE) is an American multinational pharmaceutical and biotechnology corporation that is known for discovering, developing, and manufacturing healthcare products, including innovative medicines and vaccines. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
